SCIENTIFIC Publishing Limited

ENT Updates

https://ojs.ukscip.com/index.php/ENTU

Review

Ciprofloxacin in Otitis Externa Management: Efficacy, Safety, and Future Directions

Wajan Alqathanin [1], Mohammed Kanan [2,*], Khulud Ghazwani [3], Sarah Alsaggaf [4], Renad A. Alshehri [5], Wasayef Alqhtani [3], Abeer Alamri [3], Alya Alhider [1], Wajin Alruwili [6], Sarah Saeed [3], Banan Alsufayan [7], Afnan Algarni [7], Banh Alghadyah [7], Amjad S. Alqarni [1] and Naif Al-Rasheedi [8]

[1] Department of Doctor of Pharmacy, College of Pharmacy, King Khalid University, Abha 62521, Saudi Arabia

[2] Department of Pharmacy, Rafha General Hospital, Northern Border Health Cluster, Rafha 76321, Saudi Arabia

[3] Department of Doctor of Pharmacy, Armed Forces Hospital Southern Region, Khamis Mushait 62413, Saudi Arabia

[4] Department of Doctor of Pharmacy, King Abdulaziz University, Jeddah 22254, Saudi Arabia

[5] Department of Internal Medicine, College of Medicine, King Khalid University, Abha 62521, Saudi Arabia

[6] Department of Doctor of Pharmacy, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 34212, Saudi Arabia

[7] Department of Doctor of Pharmacy, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh 11564, Saudi Arabia

[8] Pharmaceutical Services Department, Northern Area Armed Forces Hospital, King Khalid Military City, Hafr Al Batin 31991, Saudi Arabia

[*] Correspondence: ii_kanan101@outlook.com

Received: 3 April 2025; **Revised:** 7 May 2025; **Accepted:** 21 May 2025; **Published:** 8 June 2025

Abstract: Ciprofloxacin, a fluoroquinolone antibiotic, plays a crucial role in treating otitis externa, which is a common inflammatory disorder of the outer ear canal. This review examines the effectiveness and safety of ciprofloxacin in managing otitis externa, with a focus on its pharmacological properties, antibacterial effects, and outcomes. This review highlights the potent activity of ciprofloxacin against the primary pathogens *Pseudomonas aeruginosa* and *Staphylococcus aureus* and its ability to penetrate the auditory canal, making it ideal for treating ear infections. The use of oral ciprofloxacin in severe cases, particularly in malignant otitis externa, is also discussed. This review explores the benefits and drawbacks of topical and oral ciprofloxacin formulations and the rationale for combining these routes in complex cases. Special attention should be given to prescribing ciprofloxacin to vulnerable populations, such as children, the elderly, and pregnant women. The increasing prevalence of ciprofloxacin-resistant bacteria and the importance of antimicrobial stewardship programs in combating resistance are emphasized. This review addresses drug interactions and monitoring strategies. Future directions in otitis externa treatment are discussed, including the development of safer quinolones, advancements in targeted drug delivery systems, and progress in diagnostic tools for antibiotic selection. This review underscores the significance of ciprofloxacin in managing otitis externa while highlighting the need for judicious use and research to optimize outcomes and mitigate resistance risk.

Keywords: Otitis Externa; Ciprofloxacin; Antimicrobial Resistance; Antibiotics; Efficacy; Safety

1. Introduction

Otitis externa, or "swimmer's ear," is an inflammatory disorder of the outer ear canal, mainly caused by bacterial infections but also by fungal or viral sources. It often affects individuals involved in water activities due to ear canal moisture. The main bacteria are *Pseudomonas (P.) aeruginosa* and *Staphylococcus (S.) aureus* [1, 2]. The risk factors include moisture exposure, ear canal injury, allergies, and narrow ear canals.

The main symptoms include severe ear discomfort, especially when touching the outer ear, itching and irritation, inflammation and redness, fluid discharge, clear or pus-like, ear fullness, and temporary hearing loss due to blockage [2]. The diagnosis involves clinical assessment with otoscopic examination and patient history. Culture tests may identify the causative organisms [2]. Treatment includes topical antibiotics, sometimes with corticosteroids [2, 3], pain management, professional ear cleaning, and advising against water exposure and ear trauma.

Oral antibiotics are used in cases of cellulitis beyond the ear canal or in coexisting conditions [2]. Prevention includes drying the ears after water exposure, avoiding foreign objects, using earplugs while swimming, and managing skin conditions [2]. With appropriate treatment, symptoms usually resolve within one to two weeks. Without treatment, the infection may become chronic [2, 3].

Necrotizing otitis externa is severe in immunocompromised patients with diabetes and requires aggressive treatment and extended antibiotics [4, 5]. This form can be life threatening and may require hyperbaric oxygen therapy [6]. Otitis externa is common and manageable; however, prompt diagnosis and treatment are crucial to prevent complications. Maintaining ear hygiene and avoiding risk factors are key to reducing infection.

This narrative review assesses the therapeutic effectiveness and safety of ciprofloxacin in the treatment of otitis externa. The pharmacological properties, antibacterial effects, and treatment outcomes of these drugs were evaluated. This review investigates the potential of ciprofloxacin in averting complications such as necrotizing otitis externa, while addressing concerns such as antimicrobial resistance and side effects. It examines how ciprofloxacin is administered in various patient groups, including immunocompromised individuals and those with specific anatomical susceptibilities, with the aim of developing improved usage protocols.

2. Methodology

This narrative review examined the peer-reviewed literature to elucidate the role of ciprofloxacin in the treatment of otitis externa. The review focused on studies evaluating topical and oral formulations of ciprofloxacin, with or without corticosteroids, and their efficacy against pathogens such as *P. aeruginosa* and *S. aureus*. Special attention was given to research involving high-risk populations, including children, the elderly, individuals with diabetes, and those with compromised immune systems.

The inclusion criteria required studies published between 2000 and 2024 to ensure clinically relevant insights into treatment. Only English-language articles were included. Studies were identified through keyword searches in PubMed, Scopus, and Web of Science, using terms such as "ciprofloxacin," "otitis externa," "necrotizing otitis externa," "antibiotic resistance," and "fluoroquinolone safety." Additional references were obtained by screening the citations of the selected articles.

Studies were selected based on their relevance to the pharmacological, clinical, and microbiological roles of ciprofloxacin for otitis externa. The selection included original research, clinical trials, systematic reviews, meta-analyses, case reports, and narrative reviews. Priority was given to studies comparing ciprofloxacin with other antibiotics, particularly fluoroquinolones, cephalosporins, and aminoglycosides.

Articles were excluded if they focused solely on unrelated infections (e.g., otitis media, sinusitis), fungal otitis externa without reference to ciprofloxacin, or discussed other antibiotics without a comparative analysis. Non-clinical studies involving animal models or in vitro experiments were excluded unless they had clear clinical implications. Editorials, expert commentaries, and conference abstracts lacking peer review or sufficient data were also omitted. As a narrative review, no formal quality assessment of the included studies was conducted; however, the primary criterion for selection was relevance to the clinical application of ciprofloxacin in otitis externa.

A thematic assessment organized the findings into key categories, including ciprofloxacin mechanism of action, clinical results, resistance patterns, and safety profiles. This review also examines global practices and innovations in ciprofloxacin formulations, emphasizing approaches to enhance patient outcomes and combat the development of resistance.

3. Significance of Effective Antimicrobial Treatment to Prevent Complications

3.1. Preventing Complications

Appropriate antimicrobial treatments quickly eliminate primary pathogens, mainly *P. aeruginosa* and *S. aureus*, preventing the infection from extending beyond the outer ear canal. This avoids issues like cellulitis or perichondritis [2, 7]. Inadequately treated acute otitis externa can evolve into chronic inflammation, which is more challenging to manage and affects patients' quality of life. Patients with chronic conditions often require intensive treatment [3].

Severe infection, predominantly affecting immunocompromised patients, may progress to necrotizing otitis externa if not properly treated, potentially leading to complications involving the skull base and cranial nerves. Research has emphasized the necessity of swift and aggressive antimicrobial treatment in these instances [4, 5, 8].

3.2. Alleviating Symptoms and Shortening Recovery

Timely and suitable antimicrobial therapy reduces symptoms like pain, itching, and discharge, improving patient comfort [2, 7]. Antimicrobial treatments can speed up infection resolution, reducing disease duration and minimizing disruption to daily activities [2, 7].

3.3. Combating Antibiotic Resistance

Choosing correct antimicrobial agents based on probable pathogens and local resistance patterns is crucial for minimizing the development of antibiotic resistance [4]. Using topical antibiotics instead of systemic antibiotics, when appropriate, reduces systemic exposure and helps to prevent resistant bacterial strains [7].

3.4. Broader Public Health Impact

Effective antimicrobial treatment reduces the need for additional medical interventions and lowers healthcare costs and resource utilization. This is particularly relevant in cases of necrotizing otitis externa [5, 6]. Patients receiving effective treatment experience less discomfort and resume normal activities more quickly, leading to higher satisfaction with care [2, 7].

Effective antimicrobial treatment for otitis externa is crucial for addressing immediate symptoms, preventing severe complications, managing healthcare costs, and mitigating the risk of antibiotic resistance. Recent studies underscore the importance of tailored antimicrobial strategies to enhance patient outcomes and promote public health [2–4, 7].

4. Ciprofloxacin and Its Role in Otitis Externa Management

As fluoroquinolones, ciprofloxacin blocks bacterial DNA gyrase and topoisomerase IV, which are crucial for DNA replication and cause bacterial cell death. This mechanism is significant in the primary pathogens of otitis externa, *P. aeruginosa*, and *S. aureus* [2, 9].

The application of ciprofloxacin in otitis externa is beneficial because of its topical formulations, such as 0.2% and 0.3% solutions. These allow high drug concentrations at the infection site with minimal systemic absorption, enhancing bactericidal activity while reducing side effects and antibiotic resistance risks [10, 11]. Ciprofloxacin has shown comparable efficacy to other treatments in curing otitis externa, confirming its effectiveness [10].

Ciprofloxacin is often combined with corticosteroids, such as dexamethasone or fluocinolone acetonide, in otic preparations. This combination addresses both bacterial infection and inflammation, resulting in quicker symptom relief [11, 12]. Clinical trials have shown that this combination outperforms ciprofloxacin alone in terms of microbiological response and symptom alleviation [12].

Despite concerns about antibiotic resistance, studies suggest that high concentrations of ciprofloxacin in ototopical applications can overcome resistance. Ciprofloxacin-resistant isolates are susceptible to concentrations in commercial ototopical solutions [9]. The drug's high local concentration ensures rapid symptom relief and reduced complications, while its compatibility with corticosteroids enhances overall treatment outcomes. These characteristics confirm the importance of ciprofloxacin as a primary treatment for ear infections.

5. The External Auditory Canal: Structure and Infection Susceptibility

The external auditory canal (EAC) transmits sound to the tympanic membrane but is prone to infections such as otitis externa. Understanding their structure and vulnerability factors is crucial for preventing and treating these infections.

In adults, the EAC is a tube-like structure approximately 2.5 cm long, stretching from the outer ear (pinna) to the tympanic membrane. It consists of two parts: the exterior cartilaginous section and interior bony section. The canal is covered with skin that contains hair follicles and glands, including ceruminous and sebaceous glands that produce earwax (cerumen). Cerumen captures dust and microorganisms and maintains an acidic environment that inhibits bacterial growth [2].

5.1. Susceptibility to Infection

The shape of the EAC can retain moisture and foster bacterial proliferation, particularly *P. aeruginosa*, a frequent cause of otitis externa [2].

Excessive accumulation can lead to blockage, creating a dark and damp environment ideal for microbial growth [2].

The sensitive skin lining the EAC can be injured by cotton swabs, hearing aids, or fingernails, providing entry points for pathogens [13].

Disorders such as eczema or psoriasis can compromise the skin lining the EAC, increasing vulnerability to infection [2].

Narrow or winding ear canals can hinder proper drainage and ventilation, thereby elevating the risk of infection [14].

5.2. Defense Mechanisms

The protective features of EACs help to ward off infections. A slightly acidic pH inhibits bacterial growth, and the antimicrobial properties of cerumen create a barrier against pathogens [2]. The disruption of these protective mechanisms can increase the likelihood of infection.

While the EAC's structure and environment can make it susceptible to infections, understanding these factors can guide strategies for preventing and managing conditions, such as otitis externa. Approaches include maintaining ear hygiene, avoiding trauma, and controlling moisture exposure, which are essential for minimizing the risk of infection [2, 13].

6. Primary Causative Organisms

6.1. *Pseudomonas aeruginosa*

P. aeruginosa is a Gram-negative, opportunistic pathogen thriving in damp environments, making it a frequent cause of otitis externa [2]. It has various virulence factors, including toxins, biofilm-forming abilities, and enzymes such as elastase, that break down host tissues [2, 15]. Biofilm formation shields *P. aeruginosa* from host immune defenses and antimicrobial agents [15]. *P. aeruginosa* infections typically cause intense discomfort, inflammation, and pus discharge. It is also the main culprit in malignant otitis externa, a severe form affecting immunocompromised patients [15, 16].

6.2. *Staphylococcus aureus*

S. aureus is a Gram-positive bacterium that normally inhabits the skin and nasal passages but can become pathogenic [2]. It has numerous virulence factors, such as toxins and enzymes, including coagulase and hemolysins, aiding in tissue invasion and immune system evasion [2]. In otitis externa, *S. aureus* often leads to furunculosis or localized abscesses in the ear canal, causing pain and swelling [2, 17]. *S. aureus* infections may require specific antimicrobial treatment to avoid complications.

6.3. Additional Potential Pathogens

Other microorganisms occasionally cause otitis externa, particularly in chronic or complex cases. These include fungal pathogens, such as Aspergillus and Candida species, which are more common in chronic otitis externa and humid climates [2, 17]. Other bacteria, such as non-tuberculous mycobacteria and Proteus species, may be involved, although less frequently [18].

Identifying the common pathogens in otitis externa is crucial for effective treatment. Antimicrobial therapy often targets specific bacteria, with topical antibiotics being the primary approach. Customizing the treatment based on the causative organism can improve outcomes and decrease the risk of complications. Understanding the microbiome of infected ears and potential antibiotic resistance is essential for guiding treatment strategies and promoting the responsible antimicrobial use [17, 19]. **Table 1** lists the otitis externa pathogens and their responses to ciprofloxacin treatment.

Table 1. Summary of Common Pathogens in Otitis Externa and Ciprofloxacin Efficacy.

	Pathogen	Type	Association with Otitis Externa	Ciprofloxacin Effectiveness
1.	*Pseudomonas aeruginosa*	Gram-negative bacteria	Most common; causes acute and malignant otitis externa	Highly effective (topical and oral); resistance increasing
2.	*Staphylococcus aureus*	Gram-positive bacteria	Common; causes furunculosis and abscesses	Effective against MSSA; less effective for MRSA
3.	Aspergillus species	Fungi	Chronic cases, humid environments	Not effective (antifungals required)
4.	Candida species	Fungi	Chronic/recurrent infections	Not effective (antifungals required)
5.	Proteus species	Gram-negative bacteria	Uncommon, chronic/refractory cases	Moderate activity; use alternative antibiotics if resistant

MSSA: Methicillin-Susceptible *Staphylococcus aureus*; MRSA: Methicillin-Resistant *Staphylococcus aureus*.

7. Factors Contributing to Bacterial Otitis Externa

Moisture facilitates bacterial growth in patients with otitis externa. Water exposure leads to moisture accumulation, promoting the growth of pathogens such as *P. aeruginosa* and *S. aureus* [2, 16]. High humidity can increase the risk of infection [20].

Ear canal damage enhances bacterial colonization of the ear. Cotton swabs, earplugs, and hearing aids can cause microtrauma, compromising the skin's protective barrier [2].

Immunocompromised individuals, especially those with diabetes, are more susceptible to otitis externa, including severe forms such as malignant otitis externa [2, 15, 16].

Dermatological conditions, such as eczema, weaken the skin barrier of the ear canal, enabling bacterial invasion [2].

Narrow or curved ear canals impede drainage, leading to moisture retention and bacterial growth [2, 20].

Excessive cerumen can trap water and debris, creating conditions for infection [2].

Individuals with a history of otitis externa are prone to recurrence [2].

Prevention requires proper ear hygiene, limited water exposure, avoidance of canal trauma, and management of underlying conditions. High-risk individuals should use protective measures, such as earplugs, while swimming [2, 20].

8. Mode of Action

Ciprofloxacin suppresses two critical bacterial enzymes, DNA gyrase and topoisomerase IV, which are essential for DNA replication, transcription, and cell division.

DNA gyrase creates negative supercoils in DNA, reducing torsional strain during replication and transcription. Ciprofloxacin stabilizes the DNA-gyrase complex, preventing DNA strand re-ligation and leading to DNA breaks and bacterial cell death [21].

Topoisomerase IV is crucial for separating intertwined daughter DNA molecules after replication. Ciprofloxacin stabilizes the enzyme-DNA complex, hindering DNA strand separation, disrupting cell division, and contributing to bactericidal effects [22].

9. Broad-Spectrum Activity Against Gram-Negative and Gram-Positive Bacteria

Ciprofloxacin, a fluoroquinolone, offers extensive antimicrobial coverage, targeting various Gram-negative and some Gram-positive bacteria, making it essential in combating numerous bacterial infections.

9.1. Ciprofloxacin Is Particularly Potent Against Several Gram-Negative Bacteria

Pseudomonas aeruginosa: Known for antibiotic resistance and nosocomial infections, it remains susceptible to ciprofloxacin. It is one of the few oral options often used with agents such as murepavadin to enhance efficacy [23].

Escherichia coli: A common cause of urinary tract infections (UTIs), including some ceftriaxone-resistant strains, is effectively treated by ciprofloxacin due to its high urine concentration [24].

Klebsiella pneumoniae: Effective against this respiratory and bloodstream pathogen, though resistance concerns arise from DNA gyrase and topoisomerase IV mutations [25].

Neisseria gonorrhoeae: Once a standard treatment, the effectiveness of ciprofloxacin has diminished due to increased resistance from low-level environmental exposure [26].

9.2. Ciprofloxacin Also Acts Against Select Gram-Positive Bacteria

Staphylococcus aureus: Effective against methicillin-sensitive strains but less reliable for methicillin-resistant *S. aureus*. Novel delivery methods, such as ciprofloxacin-loaded niosomes, show promise for overcoming resistance and biofilm formation [27].

Bacillus anthracis: Food and Drug Administration approved for anthrax treatment and prevention, highlighting its role in bioterrorism response.

Streptococcus pneumoniae: Although not the primary choice, ciprofloxacin can be used against certain strains of respiratory infections.

9.3. Safety Considerations and Resistance

Although generally well tolerated, ciprofloxacin may cause side effects such as gastrointestinal issues and tendonitis. Resistance can develop through target enzyme mutations or increased efflux pump activity, emphasizing the need for judicious use [25, 28].

Ciprofloxacin's broad-spectrum efficacy against many gram-negative and select gram-positive bacteria makes it a valuable agent for diverse infections. However, its use must be carefully managed to minimize resistance development, necessitating prudent prescription practices and consideration of combination therapies to maximize its effectiveness [23, 29].

10. Pharmacokinetics

Ciprofloxacin is readily absorbed orally with 70–80% bioavailability. It is extensively distributed and achieves therapeutic concentrations in most tissues and fluids. The drug undergoes minimal hepatic metabolism, with a substantial portion excreted unchanged in the urine. Its elimination half-life is approximately 4–6 h, allowing twice-daily dosing [21].

Ciprofloxacin is often preferred for the treatment of ear infections because of its robust pharmacokinetic profile and excellent tissue penetration. Ciprofloxacin solutions ensure high local concentrations that are crucial for overcoming pathogen resistance. Research shows ciprofloxacin is non-inferior to other treatments for otitis externa, demonstrating effectiveness in therapeutic cure rates and microbiological eradication [10, 30].

10.1. Auditory Canal Penetration

Ciprofloxacin penetration of the auditory canal is effective in treating ear infections including otitis externa. Topical formulations deliver high local concentrations directly to the infection site, ensuring potent antimicrobial activity, while minimizing systemic exposure and side effects. It is beneficial against common ear pathogens such as *P. aeruginosa* and *S. aureus* [10, 12].

The antibiotic penetrates bacterial biofilms in the ear canal, enhancing its efficacy in eradicating biofilm-associated infections, which is a common challenge in treating chronic ear infections [9].

11. Clinical Applications of Oral Ciprofloxacin in Otitis Externa

When bacterial otitis externa is intense or unresponsive to local treatment, oral ciprofloxacin is recommended. This systemic approach achieves sufficient drug concentrations to tackle persistent infections despite topical therapy. Ciprofloxacin's effectiveness against *P. aeruginosa*, a frequent cause of these infections, is well-established [10, 12].

Oral ciprofloxacin is beneficial in conditions such as malignant otitis externa, an aggressive infection that affects the base of the skull and nearby structures. This ailment often affects individuals with compromised immune systems, such as those with diabetes, and requires systemic treatment owing to potential complications such as facial nerve paralysis and Lemierre's syndrome [4, 31, 32]. Oral ciprofloxacin, often combined with other antibiotics such as ceftazidime, effectively manages these complex cases owing to its superior tissue penetration, including bone [5, 30].

For patients unable to use topical therapies owing to allergies, anatomical challenges, or blockages that hinder effective medication delivery, oral ciprofloxacin is a feasible option. Despite such obstacles, systemic administration ensures proper infection treatment [9, 30].

Oral ciprofloxacin is vital for the treatment of ear infections when local therapies are inadequate or impractical. Its systemic reach and potency against key pathogens make it essential for severe infections, those extending beyond the external auditory canal, and for patients with contraindications to topical treatments. The choice to use oral ciprofloxacin should be based on a thorough assessment of the intensity of the infection, implicated pathogens, and patient-specific factors, ensuring that its advantages outweigh potential risks [5, 31].

12. Clinical Evidence, Dosage, Duration, and Administration

Alleviating symptoms: Research shows that oral ciprofloxacin effectively mitigates symptoms such as discomfort, swelling, and ear discharge in severe or persistent bacterial otitis externa. It is effective in cases involving resistant microorganisms, in which topical therapies have failed. Ciprofloxacin can impede pathogen growth at high concentrations achievable through systemic administration despite varying resistance levels [9].

Eliminating pathogens: Studies have shown that ciprofloxacin can target and eliminate common bacteria associated with otitis externa, such as *P. aeruginosa* and *S. aureus*. This is vital in preventing progression to more severe forms, such as malignant otitis externa, where the infection may spread beyond the external ear canal [10, 33].

Dosage: For adults with severe otitis externa, the recommended oral dose is 500 mg twice daily. Dose adjustments may be required based on kidney function and infection severity [33].

Duration: Treatment usually lasts 7–14 days, customized according to patient response and infection severity. In more complex cases of malignant otitis externa, treatment may extend up to 6 weeks to ensure complete resolution [5, 33].

Administration: Ciprofloxacin should be taken with a full glass of water, with or without food. Simultaneous consumption of dairy products or calcium-enriched drinks should be avoided to prevent reduced absorption. Maintaining proper hydration is crucial to avoid crystalluria [33].

Oral ciprofloxacin is effective in treating severe bacterial otitis externa, especially when topical treatment is unsuitable. Its ability to alleviate symptoms and eliminate pathogens makes it valuable for the management of complex cases. Healthcare providers should consider the appropriate dosage and duration based on individual patient needs to ensure effective treatment while minimizing adverse effects and antibiotic resistance.

13. Oral vs. Topical Ciprofloxacin

13.1. Benefits of Oral Treatment

Oral ciprofloxacin is crucial for infections spreading beyond the outer ear canal, such as malignant otitis externa with systemic dissemination concerns. Systemic antibiotics target deeper tissue involvement and complications [5, 33]. Oral administration benefits individuals who are unable to use topical treatments because of allergies, anatomical barriers, or adherence challenges.

13.2. Drawbacks of Oral Treatment

Oral ciprofloxacin is associated with higher systemic adverse effects, including digestive issues, tendon inflammation, and drug interactions, potentially restricting its use [34]. Systemic administration can contribute to antibiotic resistance if not used prudently, necessitating careful patient selection and adherence [9].

13.3. Advantages of Topical Application

Topical ciprofloxacin achieves high local concentrations at the infection site, boosting its effectiveness while reducing systemic exposure, which is beneficial for localized infections [10, 12]. Topical treatment results in fewer systemic side effects than oral administration, making it a safer option for many patients [34].

13.4. Drawbacks of Topical Application

Topical therapy is less effective for infections involving deeper tissues or extending beyond the external ear canal [33]. Correct application can be challenging, especially in children or in those with anatomical abnormalities, potentially impacting efficacy [10].

13.5. Reasons for Combining Oral and Topical Treatments

In severe otitis externa cases, especially those resistant to standard treatments or involving extensive tissue damage, a combination of oral and topical ciprofloxacin may be necessary. Severe or refractory infections can benefit from a combination of systemic and local therapies, providing comprehensive pathogen eradication [34]. Patients with malignant otitis externa often require aggressive treatments. Combining oral and topical ciprofloxacin helps to manage local infections while addressing systemic spread risks [5]. For immunocompromised patients, such as those with diabetes or undergoing chemotherapy, a combined approach enhances protection against dissemination and complications [5, 33].

The choice between oral and topical ciprofloxacin or their combination should be based on infection severity and extent, patient-specific factors, and systemic involvement risk. While topical therapy is effective for localized infections with minimal systemic side effects, oral therapy provides the necessary systemic coverage in severe cases. In certain scenarios, combined approaches may offer the most comprehensive treatment strategy for cases of complex otitis externa. **Table 2** compares topical and oral ciprofloxacin formulations, highlighting their uses and effects.

Table 2. Comparative Overview of Ciprofloxacin Formulations for Otitis Externa.

	Parameters	Topical Ciprofloxacin	Oral Ciprofloxacin
1.	Formulation type	Otic solution	Tablet/Suspension
2.	Typical concentration	0.2% or 0.3%	250–750 mg
3.	Route of administration	Topical (Ear canal)	Oral (Systemic)
4.	Common indications	Localized otitis externa	Severe or unresponsive cases, malignant otitis externa
5.	Advantages	High local concentration, low systemic exposure, reduced side effects	Systemic coverage, effective against deep infections
6.	Limitations	Not effective for deep infections or anatomical barriers	Risk of systemic side effects, resistance, contraindicated in certain populations

MSSA: Methicillin-Susceptible *Staphylococcus aureus*; MRSA: Methicillin-Resistant *Staphylococcus aureus*.

14. Adverse Effects of Oral Ciprofloxacin

14.1. More Common

Nausea and vomiting are prevalent among patients taking ciprofloxacin and are often mild to moderate in severity. Taking medication with food may help to alleviate these symptoms.

Diarrhea occurs due to disruption of the gut flora and, in some cases, can lead to more severe conditions, such as antibiotic-associated colitis. Headaches are frequently reported by patients and are usually mild and transient, but can still affect daily activities.

Dizziness can impair balance and coordination, necessitating precautions, such as avoiding driving or operating heavy machinery, until patients understand how ciprofloxacin affects them.

14.2. Less Common

Neuropsychiatric Effects are relatively rare, and ciprofloxacin can induce neuropsychiatric adverse drug reactions (ADRs) with an incidence of 3.6% in certain populations. These effects are more common in older adults and in those with a history of neuropsychiatric disorders [35]. Cases of acute delirium and myoclonus have also been reported, highlighting the need for careful monitoring, especially in vulnerable patients [36, 37].

Ciprofloxacin has been linked to tendonitis and tendon rupture, particularly in older patients and in those concurrently using corticosteroids. These musculoskeletal adverse effects can occur rapidly and may persist even after drug discontinuation [38].

Rare instances of ciprofloxacin-induced kidney issues such as crystal nephropathy have been documented, particularly in patients with pre-existing renal impairment [39]. Additionally, cases of syndrome of inappropriate antidiuretic hormone secretion have been reported, suggesting careful monitoring of sodium levels during treatment [40].

14.3. Managing Side Effects

Consuming ciprofloxacin in food and ensuring adequate hydration can help reduce gastrointestinal side effects. Probiotics may also be beneficial in maintaining the balance of gut flora.

Patients experiencing headaches or dizziness should rest and avoid tasks that require high concentration. These symptoms typically resolve as the body adjusts to the medication.

Though generally well tolerated, ciprofloxacin may cause gastrointestinal and neurological side effects. Proactive management of these risks can enhance patient adherence and clinical outcomes.

15. Serious Adverse Effects

The following effects require careful patient evaluation and supervision to minimize potential risks.

Ciprofloxacin usage has been associated with tendon rupture, particularly affecting the Achilles tendon, which is a severe adverse reaction. Although relatively uncommon, certain factors elevate the risk, including advanced age, simultaneous corticosteroid use, and impaired renal function. Studies have suggested that ciprofloxacin may disrupt collagen production, leading to tendon weakness and increased susceptibility to rupture. Patients experiencing sudden pain, swelling, or difficulty moving should seek immediate medical care and stop taking the medication [38, 41, 42].

Another significant side effect is QT prolongation, which can potentially progress to dangerous arrhythmias, such as torsades de pointes. This risk is elevated in individuals with existing cardiac conditions, electrolyte imbalances, or other medications known to prolong QT interval. Although ciprofloxacin has a lower risk than other fluoroquinolones such as moxifloxacin, caution is still necessary. High-risk patients should undergo regular ECG monitoring, and alternative antibiotics should be considered when appropriate [43, 44].

Peripheral neuropathy, characterized by nerve damage resulting in pain, tingling, numbness, or weakness, has been reported to be an adverse effect of ciprofloxacin. These symptoms can develop quickly and may persist even after drug discontinuation. Patients should be educated about these signs and instructed to promptly report unusual sensations. Immediate cessation of ciprofloxacin upon symptom onset is crucial to prevent irreversible damage [35, 37].

These serious adverse events underscore the importance of careful patient assessment and monitoring. Healthcare providers must evaluate individual risk factors and ensure that patients are thoroughly informed about potential side effects with clear instructions on when to seek medical attention.

16. Vulnerable Populations: Key Considerations for Oral Ciprofloxacin Prescription

The administration of oral ciprofloxacin to vulnerable groups, such as children, older adults, and expectant mothers, requires careful consideration because of their unique physiological characteristics and risk factors.

16.1. Pediatric Patients

Ciprofloxacin use in children is limited because of concerns regarding cartilage growth and joint health. However, it may be prescribed for complex urinary tract infections or severe bacterial infections when the benefits

outweigh the risks. Research suggests minimal risks when used appropriately [41, 42]. Dosing for children must be based on body weight and kidney function to reduce the adverse effects. Healthcare providers should monitor for musculoskeletal complications, although the risk of tendon rupture is not significantly higher in children [42].

16.2. Geriatric Patients

Elderly individuals are more prone to ciprofloxacin-related side effects, including tendon rupture, QT interval prolongation, and neuropsychiatric disturbances, owing to age-related organ function changes and multiple health conditions [35, 41, 44]. Dose adjustments are often required to prevent drug accumulation and toxicity due to age-related decline in kidney function. Regular monitoring of renal function is recommended [45, 46]. The potential for drug interactions is higher in older adults owing to polypharmacy. A thorough review of the patient's medication regimen is crucial to avoid adverse interactions, particularly with drugs that could exacerbate QT prolongation [44].

16.3. Pregnant Patients

Ciprofloxacin is generally not recommended during pregnancy because of potential risks to the developing fetus. Animal studies have shown evidence of harm, although direct human data are limited. Risks include possible teratogenic effects and effects on fetal development [38]. When feasible, alternative antibiotics with a better safety profile should be used for pregnant women. If ciprofloxacin is necessary, it should be used cautiously to ensure that the benefits to the mother outweigh the potential risks to the fetus [38].

Prescribing ciprofloxacin to vulnerable populations requires a sophisticated understanding of its risks and benefits. In children, the potential impact on growth and joint health must be carefully evaluated. In older adults, there is an increased vulnerability to adverse effects and drug interactions, necessitating close monitoring and dosage adjustments. Fluoroquinolones should be avoided in pregnant women.

16.4. Comparative Safety of Alternative Antibiotics

The use of ciprofloxacin in at-risk groups requires careful consideration of safer alternatives. Amoxicillin-clavulanate is preferred for pregnant women due to its safety, unlike ciprofloxacin, which poses a risk to fetal cartilage development [42]. In children, cephalexin and amoxicillin-clavulanate are safer for non-Pseudomonas infections, given the musculoskeletal toxicity risks associated with fluoroquinolone use [43]. For older adults or those with cardiovascular issues, levofloxacin provides similar coverage but risks QT prolongation and tendon rupture; thus, non-fluoroquinolones may be preferred [47]. However, these alternatives may not be effective against resistant Pseudomonas strains, necessitating individualized risk-benefit assessments and pathogen considerations.

17. Development of Antibiotic-Resistant Bacteria

17.1. *Pseudomonas aeruginosa*

P. aeruginosa has defense mechanisms, including a sturdy cell wall and efflux pump systems that remove antibiotics like ciprofloxacin. It develops resistance through alterations in the target enzymes, increased efflux pump production, and decreased outer membrane permeability. Ciprofloxacin-resistant Pseudomonas strains are increasing, particularly in hospitals, complicating infections such as pneumonia, urinary tract infections, and wound infections [48, 49].

17.2. *Staphylococcus aureus*

S. aureus, especially methicillin-resistant *S. aureus*, shows growing resistance to ciprofloxacin. Resistance mechanisms include mutations in the quinolone resistance-determining regions of DNA gyrase and topoisomerase IV and lateral transfer of resistance genes. The prevalence of ciprofloxacin-resistant Staphylococcus strains is a significant issue in community and healthcare settings, complicating treatment strategies for skin and soft tissue infections, osteomyelitis, and bacteremia [50, 51].

17.3. Strategies for Controlling Infections

Stringent infection control practices in healthcare facilities are essential for curbing the spread of drug-resistant strains. These include proper hand hygiene, isolation protocols, and thorough environmental cleansing. Monitoring

systems that track resistance patterns are vital for early detection and intervention [52].

17.4. Complementary and Alternative Treatments

When ciprofloxacin resistance is identified, alternative antibiotics or combination therapies are required. For Pseudomonas infections, options include beta-lactams, aminoglycosides, or newer drugs, such as ceftolozane/tazobactam. Alternatives for Staphylococcus infections include vancomycin, linezolid, or newer agents such as daptomycin. Ongoing research on novel antimicrobial compounds, such as lysozyme-chitosan oligosaccharide conjugates, aims to address resistant infections [51].

The rise in ciprofloxacin-resistant Pseudomonas and Staphylococcus strains poses a substantial public health challenge, requiring comprehensive management approaches. Improved infection control measures, antibiotic stewardship, and advanced alternative therapies can help to combat resistant infections.

18. Regional Resistance Patterns and Epidemiological Considerations

Antibiotic resistance patterns vary between regions, affecting the effectiveness of ciprofloxacin in treating otitis externa. In regions with high fluoroquinolone use, such as parts of Southeast Asia and Southern Europe, rising resistance *S. aureus* and *P. aeruginosa* undermines ciprofloxacin as a primary treatment [48, 50]. Countries with strong antimicrobial stewardship, such as those in Northern and Western Europe, show lower resistance and better ciprofloxacin susceptibility [19]. Research has shown that hot, humid climates in the Middle East, South Asia, and parts of Australia correlate with higher otitis externa rates and increased resistant gram-negative pathogens [20, 53]. These variations necessitate the consultation of local antibiograms to customize antibiotic therapy. Region-specific treatment guidelines are crucial for optimizing ciprofloxacin use and preventing the development of resistance [54].

19. Consequences of Excessive Antibiotic Prescription

Overuse of antibiotics has accelerated the development of antibiotic-resistant bacteria. This resistance occurs when bacteria are exposed to antibiotics unnecessarily or incorrectly, leading to mutations or acquisition of resistance genes that help them survive future treatments. This is especially concerning for pathogens like *S. aureus* and *P. aeruginosa*, which have complex resistance mechanisms and contribute to healthcare-acquired infections [48, 50].

Excessive antibiotic use increases the risk of adverse drug reactions, from minor digestive issues to severe complications, such as tendon rupture and Clostridium difficile infections. These side effects result in higher healthcare costs and increased incidence of patient illnesses [49].

Antibiotics can disrupt the human microbiome, causing dysbiosis and increasing susceptibility to opportunistic infections. This disturbance has long-term health consequences, potentially increasing the risk of metabolic and autoimmune disorders [54].

Excessive antibiotic use leads to higher healthcare costs due to extended hospital stays, additional treatments for resistant infections, and costly alternative antibiotics. This financial burden affects healthcare systems' sustainability [55].

20. Significance of Antibiotic Management Programs

Antimicrobial stewardship programs aim to improve antibiotic use by ensuring appropriate drug, dosage, and duration for each patient. This approach minimizes unnecessary antibiotic exposure and reduces the pressure for resistance development [54, 56].

Informing healthcare providers and patients about the risks of antibiotic overuse and the importance of adhering to prescribed treatments are crucial to stewardship efforts. Awareness initiatives promote responsible antibiotic use within communities [54].

Evidence-based clinical guidelines standardize treatment and reduce variations in prescription practices, helping to limit overprescription. These guidelines are regularly updated to include the latest research findings and resistance patterns [57].

Ongoing monitoring of antibiotic use and resistance patterns enables the early identification of emerging resis-

tance trends and helps tailor stewardship interventions. Tracking stewardship outcomes allows for the assessment and improvement of strategies [58].

21. Significant Drug Interactions

21.1. Antacids

Antacids with divalent and trivalent cations (e.g., magnesium, aluminum, and calcium) can impair ciprofloxacin absorption. These cations form insoluble complexes with ciprofloxacin, reducing its bioavailability and efficacy [59]. Ciprofloxacin was administered at least 2 h before or 4 to 6 h after antacid use. Informing patients about this timing can help maintain the effectiveness of antibiotics.

21.2. Non-Steroidal Anti-Inflammatory Drugs

The simultaneous use of non-steroidal anti-inflammatory drugs (NSAIDs) and ciprofloxacin may increase the risk of central nervous system (CNS) effects, including seizures. This interaction may be due to the increased solubility and bioavailability of ciprofloxacin in NSAIDs [60, 61]. Individuals with a history of seizures or CNS disorders should be monitored for CNS stimulation. Alternative pain relievers with lower interaction risks may be considered.

21.3. Additional Notable Interactions

Ciprofloxacin can impede theophylline metabolism, resulting in elevated serum levels and toxicity. Regular monitoring of theophylline concentration and dose adjustments are essential [62].

Ciprofloxacin may enhance the effects of warfarin, increasing the risk of bleeding. Monitoring the INR and adjusting the warfarin dose as needed are crucial [63].

21.4. Monitoring and Management Strategies

Using electronic health records with integrated drug interaction checking can help to identify potential interactions when prescribing [62].

Ensuring that patients and healthcare providers are aware of possible interactions and that proper medication timing and adherence are vital.

Arranging follow-up appointments to monitor patient responses and modify treatment plans is essential to manage adverse interactions.

22. Malignant Otitis Externa

Malignant otitis externa is a dangerous infection that affects the external ear canal and can potentially spread to the skull base. *P. aeruginosa* is the main causative agent, requiring prompt treatment due to its potentially fatal nature.

22.1. Etiology

Malignant otitis externa progresses from a basic ear infection owing to the invasive nature of *P. aeruginosa*. This pathogen attaches to epithelial cells, creates biofilms, and releases toxins, leading to soft tissue, cartilage, and bone invasion and potentially causing osteomyelitis. Bacterial virulence factors worsen inflammation and tissue damage.

22.2. Predisposing Factors

Diabetes mellitus is the most crucial risk factor associated with compromised immune function and poor vascular supply. Research has shown a strong correlation between diabetes and malignant otitis externa [53, 64].

Older individuals are more vulnerable to age-related immune decline and co-existing health conditions. The average age of patients is often >70 years [64, 65].

A history of ear infections can increase the susceptibility to malignant otitis externa.

Frequent exposure to wet environments increases the risk of infection by water-borne organisms such as Pseudomonas [66].

22.3. Importance of Oral Ciprofloxacin in Multi-Drug Therapy

Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, which are essential for DNA replication and repair.

Ciprofloxacin is used in combination therapy, often with intravenous antibiotics such as ceftazidime or piperacillin-tazobactam, and local treatments, including debridement and topical antibiotics. This approach ensures comprehensive coverage and improves treatment effectiveness [5, 64].

Regular monitoring of treatment responses and adverse reactions is crucial, particularly in elderly patients and those with kidney problems.

22.4. Treatment Outcomes

Early diagnosis and aggressive treatment generally lead to favorable clinical outcomes. Most patients show significant improvement and resolution of infection, especially when following a standardized treatment protocol [5].

The effective use of ciprofloxacin in combination therapy can decrease disease-related complications and enhance patients' quality of life and functional outcomes. Delayed diagnosis or treatment can result in severe complications, including cranial nerve involvement and intracranial spread [67, 68].

Insufficient treatment can lead to adverse outcomes such as facial nerve paralysis, which is associated with higher inflammatory markers and poorer prognosis [65]. Prompt management is vital to prevent such complications.

23. Alternative Treatments for Bacterial Otitis Externa

Evaluation Against Other Systemic Antibiotics

Levofloxacin, similar to ciprofloxacin may improve compliance with once-daily dosing. Both share adverse effects, including tendonitis and CNS issues, thus requiring caution in susceptible populations [69].

Amoxicillin-clavulanate targets *S. aureus* and various other bacteria, but not Pseudomonas. Its tolerability is comparable to that of fluoroquinolone contraindications, particularly when Pseudomonas is not the main pathogen [47].

Cephalexin is effective against Staphylococcus infections, but not Pseudomonas. Its safety profile suits pediatric and adult patients when Pseudomonas is not involved [66].

24. Importance of Non-Antibiotic Approaches

Cleaning the ear canal removes debris, earwax, and discharge, enhancing the efficacy of topical treatment and alleviating symptoms by improving the penetration of topical agents [3, 66].

Pain management is crucial for ensuring patient comfort and treatment adherence. NSAIDs or acetaminophen are frequently prescribed, with monitoring for adverse effects, particularly in patients with renal or gastrointestinal concerns [3].

Topical acetic acid solutions help dry the ear canal and modify the pH to inhibit bacterial growth, serving as preventive measures or adjunctive therapies with antibiotics, particularly in recurrent cases [3, 70].

25. Limitations and Contraindications of Ciprofloxacin

Ciprofloxacin increases the risk of tendonitis and rupture, especially in elderly patients, those on corticosteroids, and those with tendon disorders. This should be avoided in high-risk groups with alternative antibiotics [68].

Ciprofloxacin may cause CNS side effects, including seizures, especially in patients with preexisting CNS conditions. Monitoring or alternative treatments are advisable [68].

Concerns about cartilage and joint development limit the use of ciprofloxacin in the pediatric population. It should be used cautiously to weigh the benefits against risks [9].

Ciprofloxacin is generally avoided during pregnancy and lactation because of its potential adverse effects on fetal development. Amoxicillin-clavulanate is preferred as a safer alternative [47].

26. Conclusions and Future Directions

Ciprofloxacin remains an essential treatment for otitis externa because of its effectiveness, bactericidal properties, and excellent tissue penetration. Its availability in topical and oral forms allows for treatment strategies based on the severity of the condition and patient needs. Combined with corticosteroids, ciprofloxacin fights infection and speeds symptom relief by reducing inflammation.

However, the increasing resistance of *P. aeruginosa* and *S. aureus* strains, along with systemic side effects in susceptible groups, necessitates careful, evidence-based prescribing. Clinical decisions should follow antimicrobial stewardship, local resistance patterns, and patient monitoring to maintain the effectiveness of these drugs.

Otitis externa treatment is set to improve with advancements in drug development, delivery methods, and diagnostics, aiming to enhance its effectiveness, reduce side effects, and improve patient outcomes.

26.1. Creating Safer Quinolones

Research aims to develop quinolones with better safety profiles, reducing risks such as tendonitis and CNS effects associated with fluoroquinolones such as ciprofloxacin. Scientists are modifying structures and targeting specific bacterial enzymes to minimize unintended interactions, offering safer options for vulnerable groups, including the elderly and those with multiple health conditions [71]. These advancements aim to combat bacterial resistance, while reducing toxicity [71].

26.2. Advancements in Targeted Drug Delivery for Ear Infections

Nanoparticle-based drug delivery systems enhance antibiotic penetration and retention in the ear canal, improving therapeutic efficacy while minimizing systemic exposure and adverse reactions [72]. However, these systems face challenges, including limited stability and solubility, compared to conventional treatments. Recent innovations, such as biodegradable gels and films, have enabled localized antibiotic release at infection sites, maintaining therapeutic concentrations over extended periods. This approach reduces the need for systemic antibiotics and their associated side effects [73, 74]. Additionally, microneedle patches for transdermal delivery provide pain-free local drug concentrations while minimizing systemic absorption [73].

26.3. Progress in Diagnostic Tools for Guiding Antibiotic Selection

Rapid diagnostic tools for identifying specific pathogens and their antibiotic sensitivities can significantly improve otitis externa management by enabling precise antibiotic selection, reducing broad-spectrum agent use, and combating antibiotic resistance [70].

Techniques such as polymerase chain reaction and next-generation sequencing are being adapted for rapid pathogen identification from clinical samples, providing detailed information about bacterial strains and resistance genes for targeted therapy [3, 66].

Advancements in biosensor technology aim for real-time monitoring of infection markers in the ear canal, offering immediate feedback on the infection status and treatment response. These sensors can be integrated into wearable devices for continuous monitoring and management [73].

Author Contributions

Conceptualization, W.A., M.K., and K.G.; methodology, S.A., R.A.A., and W.A.; validation, A.A., A.A., and W.A.; formal analysis, S.S., and B.A.; resources, A.A., and B.A.; data curation, A.S.A., and N.A.R.; writing—original draft preparation, W.A., M.K., and K.G.; writing—review and editing, S.A., R.A.A., W.A., A.A., A.A., and W.A.; supervision, S.S., B.A., A.A., B.A., A.S.A., and N.A.R. All authors have read and agreed to the published version of the manuscript.

Funding

This work received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Kim, S.K.; Han, S.J.; Hong, S.J.; et al. Microbiome of Acute Otitis Externa. *J Clin Med* **2022**, *11*, 7074.
2. Jackson, E.A.; Geer, K. Acute Otitis Externa: Rapid Evidence Review. *Am Fam Physician* **2023**, *107*, 145–151.
3. Di Traglia, R.; Tudor-Green, B.; Muzaffar, J.; et al. Antibiotics versus non-antibiotic treatments for acute otitis externa: A systematic review and meta-analysis. *Clin Otolaryngol* **2023**, *48*, 841–862.
4. Byun, Y.J.; Patel, J.; Nguyen, S.A.; et al. Necrotizing Otitis Externa: A Systematic Review and Analysis of Changing Trends. *Otol Neurotol* **2020**, *41*, 1004–1011.
5. Dhariwal, A.; Manjaly, J.G.; Patel, B.; et al. Management and Clinical Outcomes of 37 Patients with Necrotizing Otitis Externa: Retrospective Review of a Standardized 6-Week Treatment Pathway. *J Int Adv Otol* **2023**, *19*, 223–227.
6. Al Siyabi, A.; Al Farsi, B.; Al-Shidhani, A.; et al. Management of Malignant Otitis Externa with Hyperbaric Oxygen Therapy: A Case Series of 20 Patients. *Oman Med J* **2023**, *38*, e512.
7. Kryukov, A.I.; Gurov, A.V.; Shadrin, G.B.; et al. Efficacy and safety of topical antibiotic therapy in patients with acute external bacterial otitis: results of a retrospective study. *Vestn Otorinolaringol* **2024**, *89*, 24–27.
8. Kumaresan, K.; Suleiman, M.; Gouda, M.; et al. 919 Retrospective Analysis of the Management of Necrotising Otitis Externa Patients: A Single Centre Study. *Br J Surg* **2024**, *111*, znae163–399.
9. Trinh, K.V.; Ruoff, K.L.; Rees, C.A.; et al. Characterization of Ciprofloxacin Resistance Levels: Implications for Ototopical Therapy. *Otol Neurotol* **2021**, *42*, e887–e893.
10. Mösges, R.; Nematian-Samani, M.; Eichel, A. Treatment of acute otitis externa with ciprofloxacin otic 0.2% antibiotic ear solution. *Ther Clin Risk Manag* **2011**, *7*, 325–336.
11. Kutz Jr, J.W.; Roland, P.S.; H Lee, K. Ciprofloxacin 0.3% + dexamethasone 0.1% for the treatment for otitis media. *Expert Opin Pharmacother* **2013**, *14*, 2399–2405.
12. Chu, L.; Acosta, A.M.; Aazami, H.; et al. Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Among Patients With Acute Otitis Externa: A Randomized Clinical Trial. *JAMA Netw Open* **2022**, *5*, e2221699.
13. Burchhardt, D.M.; David, J.; Eckert, R.; et al. Trauma patterns, symptoms, and complications associated with external auditory canal fractures. *Laryngoscope* **2015**, *125*, 1579–1582.
14. Kennel, C.E.; Puricelli, M.D.; Rivera, A.L. Surgically-Relevant Anatomy of the External Auditory Canal Bulge and Scutum. *Otol Neurotol* **2019**, *40*, e1037–e1044.
15. Wiegand, S.; Berner, R.; Schneider, A.; et al. Otitis Externa. *Dtsch Arztebl Int* **2019**, *116*, 224–234.
16. Sylvester, M.J.; Sanghvi, S.; Patel, V.M.; et al. Malignant otitis externa hospitalizations: Analysis of patient characteristics. *Laryngoscope* **2017**, *127*, 2328–2336.
17. Burton, M.; Krumbeck, J.A.; Wu, G.; et al. The adult microbiome of healthy and otitis patients: Definition of the core healthy and diseased ear microbiomes. *PLoS One* **2022**, *17*, e0262806.
18. Kwon, J.; Yang, M.H.; Ko, H.J.; et al. Antimicrobial Resistance and Virulence Factors of Proteus mirabilis Isolated from Dog with Chronic Otitis Externa. *Pathogens* **2022**, *11*, 1215.
19. Nawaz, S.; Smith, M.E.; George, R.; et al. Changes in antimicrobial resistance in acute otitis media and otitis externa. *Clin Otolaryngol* **2023**, *48*, 740–747.
20. Wijesekera, A.; Chiam, X.W.; Walker, A.; et al. Effects of seasonal, geographical and demographic factors on otitis externa microbiota in Queensland, Australia. *Aust J Gen Pract* **2024**, *53*, S27–S32.
21. Pantazidou, G.; Dimitrakopoulou, M.; Kotsalou, C.; et al. Risk Analysis of Otitis Externa (Swimmer's Ear) in Children Pool Swimmers: A Case Study from Greece. *Water* **2022**, *14*, 1983.
22. Frejat, F.O.A.; Cao, Y.; Wang, L.; et al. New 1,2,4-oxadiazole/pyrrolidine hybrids as topoisomerase IV and DNA gyrase inhibitors with promising antibacterial activity. *Arch Pharm (Weinheim)* **2022**, *355*, e2100516.
23. Wei, X.; Zhou, D.; Xu, C.; et al. Murepavadin Enhances the Killing Efficacy of Ciprofloxacin against *Pseudomonas*

aeruginosa by Inhibiting Drug Efflux. *Antibiotics (Basel)* **2024**, *13*, 810.
24. Abbott, I.J.; van Gorp, E.; Cottingham, H.; et al. Oral ciprofloxacin activity against ceftriaxone-resistant Escherichia coli in an in vitro bladder infection model. *J Antimicrob Chemother* **2023**, *78*, 397–410.
25. Park, K.S.; Yang, H.S.; Nam, Y.S.; et al. Mutations in DNA Gyrase and Topoisomerase IV in Ciprofloxacin-Nonsusceptible Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae. *Clin Lab* **2017**, *63*, 535–541.
26. González, N.; Abdellati, S.; De Baetselier, I.; et al. Ciprofloxacin Concentrations 1/1000th the MIC Can Select for Antimicrobial Resistance in N. gonorrhoeae-Important Implications for Maximum Residue Limits in Food. *Antibiotics (Basel)* **2022**, *11*, 1430.
27. Kashef, M.T.; Saleh, N.M.; Assar, N.H.; et al. The Antimicrobial Activity of Ciprofloxacin-Loaded Niosomes against Ciprofloxacin-Resistant and Biofilm-Forming *Staphylococcus aureus*. *Infect Drug Resist* **2020**, *13*, 1619–1629.
28. Mulder, M.; Kiefte-de Jong, J.C.; Goessens, W.H.; et al. Risk factors for resistance to ciprofloxacin in community-acquired urinary tract infections due to Escherichia coli in an elderly population. *J Antimicrob Chemother* **2017**, *72*, 281–289.
29. Cho, D.Y.; Lim, D.J.; Mackey, C.; et al. Ivacaftor, a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator, Enhances Ciprofloxacin Activity Against *Pseudomonas aeruginosa*. *Am J Rhinol Allergy* **2019**, *33*, 129–136.
30. Kiakojuri, K.; Tavasoli, A.; Yunesi, R.; et al. Therapeutic Effects of Ciprofloxacin Powder and Drops in Chronic Bacterial Middle Ear Infections: A Clinical Trial Study. *Jundishapur J Microbiol* **2020**, *13*, e98110.
31. Dabiri, S.; Karrabi, N.; Yazdani, N.; et al. Facial nerve paralysis in malignant otitis externa: comparison of the clinical and paraclinical findings. *Acta Otolaryngol* **2020**, *140*, 1056–1060.
32. Ogi, M.; Takahashi, K.; Morita, Y.; Horii, A. Lemierre's Syndrome Due to Malignant Otitis Externa: Imaging Studies Revealed Its Systemic Dissemination. *J Int Adv Otol* **2021**, *17*, 461–464.
33. Courson, A.M.; Vikram, H.R.; Barrs, D.M. What are the criteria for terminating treatment for necrotizing (malignant) otitis externa? *Laryngoscope* **2014**, *124*, 361–362.
34. Parmar, S.M.; Chauhan, S.; Mittal, S.; et al. A Comparative Study between Topical versus Combined (Systemic plus Topical) Therapy in Ciprofloxacin-Sensitive Chronic Suppurative Otitis Media (Tubotympanic). *Indian J Otol* **2022**, *28*, 288–291.
35. Hartinger, J.M.; Dvorackova, E.; Myslivecek, M.; et al. The frequency of, and predisposing risk factors for, ciprofloxacin-induced neuro-psychiatric adverse drug reactions. *Bratisl Lek Listy* **2023**, *124*, 779–782.
36. Javed, H.; Ali, H.T.; Soliman, Z.A.; et al. Three Cases of Myoclonus Secondary to Ciprofloxacin: "Ciproclonus". *Clin Neuropharmacol* **2023**, *46*, 200–203.
37. Stroud, S.G.; Kandemir, U. Acute Delirium Induced by Ciprofloxacin in a Patient With Chronic Kidney Disease: A Case Report. *JBJS Case Connect* **2020**, *10*, e0603.
38. Ko, C.Y.; Yusoff, S.A.B.; Mackenzie, T. Biceps femoris rupture associated with ciprofloxacin use. *Intern Med J* **2021**, *51*, 808–809.
39. Kammoun, K.; Jarraya, F.; Makni, S.; et al. Ciprofloxacin-induced crystal nephropathy. *Iran J Kidney Dis* **2014**, *8*, 240–242.
40. Babar, S.M. SIADH associated with ciprofloxacin. *Ann Pharmacother* **2013**, *47*, 1359–1363.
41. Baik, S.; Lau, J.; Huser, V.; et al. Association between tendon ruptures and use of fluoroquinolone, and other oral antibiotics: a 10-year retrospective study of 1 million US senior Medicare beneficiaries. *BMJ Open* **2020**, *10*, e034844.
42. Sangiorgio, A.; Sirone, M.; Adravanti, F.M.; et al. Achilles tendon complications of fluoroquinolone treatment: a molecule-stratified systematic review and meta-analysis. *EFORT Open Rev* **2024**, *9*, 581–588.
43. Saad, N.A.; Elberry, A.A.; Matar, H.S.; et al. Effect of ciprofloxacin vs levofloxacin on QTc-interval and dysglycemia in diabetic and non-diabetic patients. *Int J Clin Pract* **2021**, *75*, e14072.
44. Briasoulis, A.; Agarwal, V.; Pierce, W.J. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. *Cardiology* **2011**, *120*, 103–110.
45. Li, X.; Zoller, M.; Fuhr, U.; et al. Ciprofloxacin in critically ill subjects: considering hepatic function, age and sex to choose the optimal dose. *J Antimicrob Chemother* **2019**, *74*, 682–690.
46. Gai, X.Y.; Bo, S.N.; Shen, N.; et al. Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria. *Chin Med J (Engl)* **2019**, *132*, 638–646.
47. Spachmann, P.J.; Fischer, S.E.; Goßler, C.; et al. Amoxicillin/Clavulanic Acid in Transrectal Biopsy of the

Prostate-An Alternative in Times of Ciprofloxacin Obsolescence and Fosfomycin Limitation? *Antibiotics (Basel)* **2024**, *13*, 940.
48. Lorusso, A.B.; Carrara, J.A.; Barroso, C.D.N.; et al. Role of Efflux Pumps on Antimicrobial Resistance in *Pseudomonas aeruginosa*. *Int J Mol Sci* **2022**, *23*, 15779.
49. Rehman, A.; Patrick, W.M.; Lamont, I.L. Mechanisms of ciprofloxacin resistance in *Pseudomonas aeruginosa*: new approaches to an old problem. *J Med Microbiol* **2019**, *68*, 1–10.
50. Guo, Y.; Song, G.; Sun, M.; et al. Prevalence and Therapies of Antibiotic-Resistance in *Staphylococcus aureus*. *Front Cell Infect Microbiol* **2020**, *10*, 107.
51. Saito, H.; Sakakibara, Y.; Sakata, A.; et al. Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against *Pseudomonas aeruginosa*, Acinetobacter baumannii and Methicillin-resistant *Staphylococcus aureus*. *PLoS One* **2019**, *14*, e0217504.
52. Orazi, G.; O'Toole, G.A. *Pseudomonas aeruginosa* Alters *Staphylococcus aureus* Sensitivity to Vancomycin in a Biofilm Model of Cystic Fibrosis Infection. *mBio* **2017**, *8*, e00873-17.
53. Yang, T.H.; Xirasagar, S.; Cheng, Y.F.; et al. Malignant Otitis Externa is Associated with Diabetes: A Population-Based Case-Control Study. *Ann Otol Rhinol Laryngol* **2020**, *129*, 585–590.
54. Majumder, M.A.A.; Rahman, S.; Cohall, D.; et al. Antimicrobial Stewardship: Fighting Antimicrobial Resistance and Protecting Global Public Health. *Infect Drug Resist* **2020**, *13*, 4713–4738.
55. Lagarde, M.; Blaauw, D. Levels and determinants of overprescribing of antibiotics in the public and private primary care sectors in South Africa. *BMJ Glob Health* **2023**, *8*, e012374.
56. Gerber, J.S.; Jackson, M.A.; Tamma, P.D.; et al. Antibiotic Stewardship in Pediatrics. *Pediatrics* **2021**, *147*, e2020040295.
57. McGregor, J.C.; Fitzpatrick, M.A.; Suda, K.J. Expanding Antimicrobial Stewardship Through Quality Improvement. *JAMA Netw Open* **2021**, *4*, e211072.
58. Zay Ya, K.; Win, P.T.N.; Bielicki, J.; et al. Association Between Antimicrobial Stewardship Programs and Antibiotic Use Globally: A Systematic Review and Meta-Analysis. *JAMA Netw Open* **2023**, *6*, e2253806.
59. KuKanich, K.; KuKanich, B.; Guess, S.; Heinrich, E. Effect of Sucralfate on the Relative Bioavailability of Enrofloxacin and Ciprofloxacin in Healthy Fed Dogs. *J Vet Intern Med* **2016**, *30*, 108–115.
60. Bag, P.P.; Ghosh, S.; Khan, H.; et al. Drug–drug salt forms of ciprofloxacin with diflunisal and indoprofen. *CrystEngComm* **2014**, *16*, 7393–7396.
61. Acebedo-Martínez, F.J.; Domínguez-Martín, A.; Alarcón-Payer, C.; et al. Enhanced NSAIDs Solubility in Drug-Drug Formulations with Ciprofloxacin. *Int J Mol Sci* **2023**, *24*, 3305.
62. Datta, A.; Flynn, N.R.; Barnette, D.A.; et al. Machine learning liver-injuring drug interactions with non-steroidal anti-inflammatory drugs (NSAIDs) from a retrospective electronic health record (EHR) cohort. *PLoS Comput Biol* **2021**, *17*, e1009053.
63. Vega, A.J.; Smith, C.; Matejowsky, H.G.; et al. Warfarin and Antibiotics: Drug Interactions and Clinical Considerations. *Life (Basel)* **2023**, *13*, 1661.
64. Hammami, F.; Koubaa, M.; Rekik, K.; et al. Malignant Otitis Externa: An Experience of A 27-Year Period. *Iran J Med Microbiol* **2022**, *16*, 296–304.
65. Hammami, F.; Koubaa, M.; Rekik, K.; et al. 1291. Malignant Otitis Externa With Facial Nerve Paralysis: Comparative Analysis. *Open Forum Infect Dis* **2023**, *10*, ofad500.1130.
66. Hertz, J.; Felding, U.A.; Astvad, K.M.T.; et al. Otitis externa. *Ugeskr Laeger* **2024**, *186*, V05230339.
67. Arsovic, N.; Radivojevic, N.; Jesic, S.; et al. Malignant Otitis Externa: Causes for Various Treatment Responses. *J Int Adv Otol* **2020**, *16*, 98–103.
68. Yigider, A.P.; Ovunc, O.; Arslan, E.; et al. Malignant Otitis Externa: How to Monitor the Disease in Outcome Estimation? *Medeni Med J* **2021**, *36*, 23–29.
69. Grillon, A.; Schramm, F.; Kleinberg, M.; Jehl, F. Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, *Pseudomonas aeruginosa* and *Stenotrophomonas maltophilia* Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies. *PLoS One* **2016**, *11*, e0156690.
70. Gelardi, M.; Giancaspro, R.; Landi, M.; et al. Perspectives of Italian Physicians and Patients in the Treatment of Otitis Externa: A Real-Life Study. *J Pers Med* **2023**, *13*, 1083.
71. Spencer, A.C.; Panda, S.S. DNA Gyrase as a Target for Quinolones. *Biomedicines* **2023**, *11*, 371.
72. Cheng, X.; Xie, Q.; Sun, Y. Advances in nanomaterial-based targeted drug delivery systems. *Front Bioeng Biotechnol* **2023**, *11*, 1177151.
73. Zhang, Z.; Li, X.; Zhang, W.; Kohane, D.S. Drug Delivery across Barriers to the Middle and Inner Ear. *Adv Funct Mater* **2021**, *31*, 2008701.

74. Delaney, D.S.; Liew, L.J.; Lye, J.; et al. Overcoming barriers: a review on innovations in drug delivery to the middle and inner ear. *Front Pharmacol* **2023**, *14*, 1207141.

Copyright © 2025 by the author(s). Published by UK Scientific Publishing Limited. This is an open access article under the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Publisher's Note: The views, opinions, and information presented in all publications are the sole responsibility of the respective authors and contributors, and do not necessarily reflect the views of UK Scientific Publishing Limited and/or its editors. UK Scientific Publishing Limited and/or its editors hereby disclaim any liability for any harm or damage to individuals or property arising from the implementation of ideas, methods, instructions, or products mentioned in the content.